Welcome to our dedicated page for Amedisys news (Ticker: AMED), a resource for investors and traders seeking the latest updates and insights on Amedisys stock.
Amedisys Inc. (NASDAQ: AMED) is a leading healthcare services company in the United States, specializing in delivering personalized home health, hospice, and high-acuity care services. Headquartered in Baton Rouge, LA, with an executive office in Nashville, TN, the company employs around 18,700 staff across 520 care centers in 37 states and the District of Columbia. Founded in 1982, Amedisys is dedicated to providing quality, clinically-distinctive care to more than 469,000 patients annually, with over 10.6 million visits each year.
Amedisys operates across four key segments: Home Health, Hospice, High Acuity Care, and Personal Care. The Home Health segment offers skilled nursing, therapy, and aid services directly in patients' homes, while the Hospice segment provides end-of-life care to terminally ill patients. The High Acuity Care segment delivers critical inpatient care elements at home, and the Personal Care segment, which was divested in March 2023, offered assistance with daily living activities.
Amedisys's commitment to high-quality care is underpinned by its comprehensive coordination with healthcare providers and personalized care plans tailored to each patient's unique needs. With a strong network involving more than 3,000 hospitals and 110,000 physicians nationwide, Amedisys is a trusted partner in post-acute care.
Recent notable achievements include a merger agreement with UnitedHealth Group, aimed at enhancing patient care through integrated services. Financially, Amedisys reported a net service revenue increase to $571.4 million for Q1 2024, reflecting a robust service demand despite divesting the Personal Care segment.
Additionally, Amedisys is actively involved in advancing healthcare technology. The company has partnered with Patient Choice Laboratories to incorporate advanced molecular testing, enhancing infection diagnosis and patient outcomes. This innovation underscores Amedisys’s commitment to leveraging cutting-edge technology to improve patient care.
For stakeholders, Amedisys remains a prominent figure in the home healthcare industry, constantly adapting and growing to meet the increasing needs of its patient population. The company's strategic partnerships and advancements in healthcare technology position it well for sustained growth and improved patient outcomes.
Mount Sinai at Home, a joint venture between Mount Sinai Health System and Contessa, expands home-based care services in the New York area. This initiative combines home health, hospitalization, rehabilitation, and palliative care under the new name, aiming to enhance care delivery. The service currently treats nearly 3,000 patients annually, boasting a 96% patient satisfaction rate and a 4-star quality rating from CMS. Driven by patient demand for home care, this initiative aligns with emerging trends in healthcare delivery.
Amedisys, Inc. (AMED) reported a decrease in net service revenue, down $6.3 million to $557.9 million for Q2 2022. Net income was $29.6 million, a significant drop from $80.1 million in 2021, with EPS falling to $0.91 from $2.43. For the six-month period, revenue rose slightly to $1,103.1 million. Adjusted EBITDA also declined to $74.4 million. The company updated its 2022 revenue guidance to $2.290-$2.310 billion while reaffirming adjusted EBITDA guidance of $275-$285 million. CEO Chris Gerard noted challenges from COVID-19 and regulatory concerns.
Amedisys (NASDAQ: AMED) will disclose its Q2 results on July 27, 2022, post-market, with a conference call scheduled for July 28, 2022, at 11:00 a.m. ET. Investors can access the call by dialing toll-free numbers or via a live webcast on the company's investor relations site. Amedisys is dedicated to providing high-quality home health, hospice, personal care, and high-acuity care services across the U.S., partnering with over 3,000 hospitals and 90,000 physicians to deliver care to more than 445,000 patients annually.
Amedisys (NASDAQ: AMED) has partnered with Memorial Hermann Health System to provide home-based medical, rehabilitation, and palliative care. This collaboration allows patients to receive acute hospital care and rehabilitation in the comfort of their homes, reducing readmission rates by 44% and hospital stays by 35%. Patients will have the option to be discharged directly from the Emergency Center and monitored remotely. This innovative approach aligns with the growing trend towards community-based healthcare and enhances patient experience.
Amedisys (NASDAQ: AMED) announced a partnership with Baylor Scott & White Health to offer innovative at-home care solutions. This collaboration aims to deliver hospital-level care, including skilled nursing and palliative support, reducing hospital readmission rates by 44% and hospital stays by 35%. The program, set to roll out in 2023, will enhance patient outcomes and satisfaction, building on Baylor Scott & White's century-long reputation for quality care. Both organizations are committed to improving patient experiences by providing more convenient care options in the comfort of home.
Amedisys, a leader in home health and hospice care, announced its participation in several upcoming investor conferences. CEO Chris Gerard and CFO Scott Ginn will present at the Benchmark Healthcare House Calls Conference on June 2, at the William Blair Growth Stock Conference on June 6, and at the Jefferies Healthcare Conference on June 8. Amedisys provides personalized healthcare services to over 445,000 patients annually and partners with more than 3,000 hospitals.
Amedisys, Inc. (NASDAQ: AMED) has been recognized as one of the 2022 Best Places to Work in Healthcare by Modern Healthcare for the second consecutive year. This distinction highlights companies that empower employees to provide exceptional care. Amedisys emphasizes creating a supportive environment for its staff, crucial during the challenges posed by the pandemic. The evaluation involved 25% from company practices and 75% from employee engagement scores. The complete list of winners will be published on September 29, 2022.
Amedisys, a home health, hospice, and personal care provider, announced a series of upcoming investor presentations. CEO Chris Gerard and CFO Scott Ginn will present at the Bank of America Securities Healthcare Conference on May 10 at 5:40 p.m. ET, the RBC Capital Markets Global Healthcare Conference on May 17, and the UBS Global Healthcare Conference on May 23 at 9:15 a.m. ET. Investors can access a live webcast of these presentations through the company’s website.
Amedisys operates nationwide, serving over 445,000 patients annually with high-quality home-based care.
FAQ
What is the current stock price of Amedisys (AMED)?
What is the market cap of Amedisys (AMED)?
What services does Amedisys Inc. provide?
Where is Amedisys Inc. headquartered?
How many employees does Amedisys have?
What is the scope of Amedisys's operations?
How many patients does Amedisys serve annually?
What recent merger has Amedisys entered into?
What recent technological advancement has Amedisys incorporated?
What was Amedisys's net service revenue for Q1 2024?
How does Amedisys coordinate patient care?
What was the Personal Care segment of Amedisys?
